[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"frontal-fibrosing-alopecia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:frontal-fibrosing-alopecia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,66,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644493","phase-2-phase-2-open-label-trial-of-delgocitinib-20-mgg-cream-in-subjects-with-frontal-fibrosing-alopecia-ffa-100644493",false,"NCT07671157","Phase 2 Open Label Trial of Delgocitinib 20 mg\u002Fg Cream in Subjects With Frontal Fibrosing Alopecia (FFA)","Inclusion Criteria:\n\n* Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any trial-related procedures.\n* Subjects must be willing to comply with all trial procedures and must be available for the duration of the trial.\n* Male or female subject aged 18 years of age or older at the time of consent.\n* Female subject of childbearing potential has had a negative serum pregnancy test at screening and negative urine pregnancy test at Day 1.\n* Subject has clinically confirmed diagnosis of FFA based on investigator judgment.\n* Subject has a target area with moderate to severe perifollicular erythema and\u002For scale at Screening and Day 1.\n* For subject who uses make-up, moisturizers, creams, lotions, cleansers, and\u002For sunscreens on the face, subject has used the same product brands\u002Ftypes for a minimum period of 4 weeks prior to Day 1, agrees not to change brand\u002Ftype or frequency of use throughout the trial, agrees not to apply those products on the treated area during the trial, and agrees not to use make-up, moisturizers, creams, lotions, cleansers, and\u002For sunscreens on the face on the clinic visit days before the visit.\n* Subject is willing to maintain a consistent hair style and hair style regimen, including shampoo and hair products (including hair dye, process, and timing to hair appointments), and to refrain from weaves or extensions throughout the course of the trial and for 4 weeks prior to Day 1. Note: Hair dying and shaving of scalp is allowed during the trial but not within 48 hours prior to a trial visit.\n\nExclusion Criteria:\n\nSubject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the trial.\n\nSubject has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.\n\nSubject is currently receiving a nonbiological investigational product or device or has received one within 4 weeks prior to Day 1.\n\nSubject has had excessive sun exposure or has used tanning booths within 4 weeks prior to Day 1 or is not willing to minimize natural and artificial sunlight exposure during the trial. Use of sunscreen products (except on treated areas for subjects in Cohort 1) and protective apparel are recommended when sun exposure cannot be avoided.\n\nHistory of other scalp\u002Fhair disease including discoid lupus erythematosus and central centrifugal cicatricial alopecia. Note: Subjects with lichen planopilaris\u002FFFA overlap are not to be excluded.\n\nPresence of active dermatologic condition that might interfere with FFA diagnosis and\u002For interfere with the trial assessments such as seborrheic dermatitis, psoriasis, or telogen effluvium.\n\nSubject who has undergone scalp reduction surgery or hair transplantation.\n\nUse of adhesive wigs during the trial.\n\nSubject is known to have immune deficiency or is immunocompromised.\n\nSubject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and\u002For localized carcinoma in situ of the cervix are not to be excluded.\n\nSubject had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the trial.\n\nSubject has any clinically significant medical condition or physical\u002Flaboratory\u002Fvital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of trial results.\n\nSubject has positive results for hepatitis B surface antigens (HBsAg), antibodies to hepatitis B core antigens (anti-HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).\n\nSubject has used treatment with agents (including natural products or nutritional supplement such as Viviscal, Nutrafol, and\u002For biotin) that may affect hair regrowth in the last 4 weeks prior to Day 1. Patients who have been on oral minoxidil or oral spironolactone for 6 or more months may continue these medications at the same doses.\n\nSubject has used intralesional scalp corticosteroids or platelet rich plasma injection in the last 4 weeks prior to Day 1.\n\nSubject has used systemic treatment with immunosuppressive\u002Fmodulating medication or medication that could affect FFA (eg, corticosteroids, methotrexate, hydroxychloroquine, retinoids, calcineurin inhibitor, tetracyclines, pioglitazone, oral JAK inhibitor, or 5-α-reductase-inhibitors) within 4 weeks prior to Day 1. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed. Note: Standard doses of systemic antihistamines are allowed.\n\nSubject has used any topical medicated treatment that could affect FFA within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, calcineurin inhibitors, phosphodiesterase-4 (PDE-4) inhibitors, topical JAK inhibitors.\n\nSubject has received any ultraviolet (UV)-B phototherapy (including tanning beds), excimer laser, or any other phototherapy within 4 weeks prior to Day 1.\n\nSubject has had psoralen-UV-A (PUVA) treatment within 4 weeks prior to Day 1.\n\nSubject has a known or suspected allergy to delgocitinib or any component of the IMP.\n\nSubject has a history of an allergic reaction or significant sensitivity to hypoallergenic ink.\n\nSubject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.\n\nSubject has prior use of delgocitinib cream as treatment for frontal fibrosing alopecia.\n\nSubject has prior failure of adequate response of frontal fibrosing alopecia to a topical JAK inhibitor or oral JAK inhibitor.\n\n\\-","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational study drug to learn whether the delgocitinib 20 mg\u002Fg cream works in treating a specific disease. \"Investigational\" means that the delgocitinib 20 mg\u002Fg cream is being studied.",[25],"Frontal Fibrosing Alopecia",[27,28,29,30],"alopecia","hairloss","FFA","frontal fibrosing alopecia","NOT_YET_RECRUITING","2026-06-22",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":19},"2026-09-10",{"date":39,"type":19},"2027-10-10",{"name":41,"class":42},"Maryanne Makredes Senna","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100632038","phase-2-deucravacitinib-in-the-treatment-of-cicatricial-alopecias-100632038","NCT07508488","Deucravacitinib in the Treatment of Cicatricial Alopecias","Inclusion Criteria:\n\n* Participants of any gender, age 18 years or older, at the time of informed consent at Screening\n* Participants who are willing and able to adhere to the study visit schedule and comply with protocol requirements.\n* Participant self-reports a history of at least 6 months of moderate-to-severe CA (FFA or CCCA). Diagnosis will be made clinically, and severity assessed with according to the FFASI32 ≥30 and\u002For CHLG ≥3.\n* Participant has a negative Tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) at screening or within the last 12 months.\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP (all female participants, regardless of whether or not they have experienced\u002Freported menarche, are considered WOCBP unless they are permanently sterile or confirmed infertile). A WOCBP who is sexually active must use a contraceptive method that is highly effective, with a failure rate of \\\u003C1%, during the intervention period and for at least 28 days after the last dose of study intervention. And if a WOCBP, must have a negative highly sensitive serum pregnancy test at the screening visit and a negative urine pregnancy test at baseline performed before the first dose of study intervention.\n* Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.\n\nExclusion Criteria:\n\n* Participant's cause of hair loss is indeterminable and\u002For they have concomitant causes of alopecia, such pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia.\n* Participant has a history of CA for \\> 5 years since the disease onset, severe fibrosing disease, or very rapid hair loss at screening.\n* Participant has a history of moderate to severe keloids on the scalp, as determined by clinical examination at screening. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.\n* Other scalp disease that may impact assessment (e.g., scalp psoriasis, dermatitis, etc.).\n* Participant is pregnant or breastfeeding.\n* Participation in other studies involving investigational drug(s) within 4 weeks or within 5 half-lives (if known), whichever is longer, prior to study entry and\u002For during study participation (de novo patients only).\n* Active systemic diseases that may cause hair loss (e.g., systemic lupus erythematosus, thyroiditis, systemic sclerosis, etc.).\n* Any Psychiatric condition in the opinion of the investigator precludes participation in the study.\n* Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (particularly thyroid disease which can be associated with hair loss), pulmonary, cardiovascular, psychiatric, immunologic\u002Frheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator, the participant is inappropriate for entry into this study, or unwilling\u002Funable to comply with STUDY PROCEDURES.\n* History of thromboembolic events including DVT and PE or history of inherited coagulopathies.\n* Any present malignancies or history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.\n* History of any lymphoproliferative disorder such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.\n* History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.\n* History of systemic infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 0.\n* Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 0 or superficial skin infection within 1 week prior to Day 0. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.\n* Considered in imminent need for surgery or with elective surgery scheduled to occur during the study.\n* Active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology at the time of screening.\n* Participant has any uncertain or clinically significant laboratory abnormalities that may affect interpretation of study data or endpoints, as determined by the PI.\n* Have an active history of alcohol or substance abuse within 1 year prior to Day 0.\n* Participant has received a live attenuated vaccine ≤ 6 weeks prior to study screening.\n* History of adverse systemic or allergic reactions to components of study drug.\n* Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, within 8 weeks prior to baseline visit.\n* Use of other non-biologic systemic agent for CA, including, 5α-reductase inhibitors, hydroxychloroquine, or retinoids, within 4 weeks prior to baseline visit.\n* Use of an intralesional corticosteroids or oral JAK inhibitor (tofacitinib, ruxolitinib, or any JAK1\u002FTYK2 product) within 4 weeks prior to the baseline visit.\n* Any previous use of a TYK2 inhibitor.\n* Participant has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus or cyclosporine within 1 week before the baseline visit.\n* Participant has been previously treated with biological drugs in the last 12 weeks for other indications.\n* Participants previously tested with a positive or indeterminable PPD or QFT result, including participants that completed standard tuberculosis therapy.",{"count":51,"type":19},20,[22],"This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline\u002FDay 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.",[55,25],"Central Centrifugal Cicatricial Alopecia","RECRUITING","2026-06-09",{"date":59,"type":35},"2026-06-10",{"date":61,"type":35},"2026-05-28",{"date":63,"type":19},"2028-09-30",{"name":65,"class":42},"Icahn School of Medicine at Mount Sinai",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":20,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":43},"100619134","facial-papules-in-frontal-fibrosing-alopecia-ffa-100619134","NCT07340671","Facial Papules in Frontal Fibrosing Alopecia (FFA)","Evaluating the Efficacy of the 1726nm Laser for the Treatment of Facial Papules in Frontal Fibrosing Alopecia (FFA)","Inclusion Criteria:\n\n* Female or Male\n* Fitzpatrick Skin Types I-VI\n* At least 18 years of age\n* Has clinically diagnosed FFA with facial papules.\n* Subject must be able to read, speak, and understand English or Spanish and sign the Informed Consent Form.\n* Willing and able to adhere to the treatment and follow-up schedule and pre\u002Fpost-treatment care instructions.\n* No contraindication to laser therapy.\n* Willing to have photographs taken of the treatment area and agree to the use of photographs for presentation, educational or marketing purposes.\n* Agree to not undergo any other procedure(s) or add any new treatment modalities in the treatment area during the study.\n* Willing to use investigator approved skincare topicals and follow investigator approved skincare regimen for the duration of the study.\n\nExclusion Criteria:\n\n* Prior treatment to the target area during participation in a clinical trial of another device or drug within 1 month (30 days) prior to study participation.\n* Prior treatment to the target area within 3 months of study participating including chemical peel, dermabrassion, microneedling, radiofrequency treatment, laser or light-based procedures, cryodestruction or chemodestruction, intralesional steroids, photodynamic therapy, or acne surgery.\n* Prior injection of botulinum toxin in the target area within 3 months of study participation and for the duration of the study.\n* Systemic use of retinoid, such as isotretinoin, within 3 months of study participation.\n* Still healing from another treatment in the target area according to investigator's discretion.\n* History of malignant tumors in the target area.\n* Pregnant and\u002For breastfeeding or planning to become pregnant during the study.\n* History of diagnosed immunosuppression\u002Fimmune deficiency or currently using immunosuppressive medications.\n* History of diagnosed connective tissue disease, such as systemic lupus erythematosus or scleroderma.\n* Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.\n* History of disease stimulated by heat, such as recurrent herpes simplex and\u002For herpes zoster (shingles) in the target area, unless treatment is conducted following a prophylactic regimen.\n* History of radiation to the target area, currently undergoing treatment for skin cancer in the target area, or undergoing systemic chemotherapy for the treatment of cancer.\n* History of diagnosed pigmentary disorders (including vitiligo) in the target area.\n* Excessively tanned in the treatment area or unable\u002Funlikely to refrain from tanning in the target area during the study.\n* History of keloids or hypertrophic scarring.\n* Prisoners\n* As per the Investigator's discretion, any physical, mental or medical condition which might make it unsafe for the subject to participate in this study, might interfere with patient's participation in the full study protocol, or might interfere with the diagnosis or assessment of facial papules.",{"count":74,"type":19},10,[76],"NA","The objective is to evaluate the safety and efficacy of the Cutera 1726 nm laser system (also referred to as AviClear) for the treatment of facial papules in frontal fibrosing alopecia (FFA).",[25],"2026-04-27",{"date":81,"type":35},"2026-05-01",{"date":79,"type":19},{"date":84,"type":19},"2027-04-28",{"name":86,"class":42},"University of Miami",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":43},"100607590","the-effectiveness-of-hydroxychloroquine-versus-methotrexate-in-the-treatment-of-frontal-fibrosing-alopecia-in-routine-clinical-care-a-patient-preference-trial-ffa-trial-100607590","NCT07190534","The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)","The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of frontal fibrosing alopecia (FFA)\n* Willing and able to provide written informed consent\n* Adequate understanding of the Dutch language\n* No known contraindications or allergies to hydroxychloroquine (HCQ) or methotrexate (MTX)\n\nExclusion Criteria:\n\n* Histopathological different diagnosis than FFA.\n* Inability to adhere to the study protocol, including medication intake, clinic visits, and questionnaire completion.\n* Patients who are ineligible for the HCQ arm (due to contraindications), are automatically included in the MTX arm.\n\nContraindications HCQ: retinopathy and\u002For maculopathy\u002Fmyasthenia gravis\u002Fbody weight less than 35 kg\n\n\\- Patients who are ineligible for the MTX arm (due to contraindications), are automatically included in the HCQ arm.",{"count":95,"type":19},50,"OBSERVATIONAL","Frontal fibrosing alopecia (FFA) is a type of scarring hair loss that mostly affects women and causes permanent hair loss. Two medicines, hydroxychloroquine (HCQ) and methotrexate (MTX), are often used to treat FFA, but it is not yet clear which treatment works better. This study aims to compare the effects of HCQ and MTX in everyday clinical care.\n\nAdults with FFA who choose to start either HCQ or MTX and will be followed for up to 48 weeks.\n\nThe main goal is to see how well each medicine helps reduce disease activity, measured by a tool called the Frontal Fibrosing Alopecia Severity Score (FFASS) after 6 months. At each clinic visit, participants will also complete short questionnaires about symptoms, quality of life, and general well-being.\n\nBy collecting this information, the study hopes to provide better evidence about how well HCQ and MTX work for FFA, which may help guide future treatment recommendations.",[25,99],"Cicatricial Alopecia",[101,29,102,103,104,105,106],"Frontal fibrosing alopecia","Cicatricial alopecia","Scarring alopecia","Hair disease","hydroxychloroquine","methotrexate","2025-09-26",{"date":109,"type":35},"2025-09-29",{"date":111,"type":19},"2025-11",{"date":113,"type":19},"2027-05",{"name":115,"class":42},"Erasmus Medical Center"]